Evaluation of 95-Gene Classifier of Formalin-fixed Paraffin-embedded Tissues in ER-positive, HER2-negative, and Node-negative Breast Cancer

被引:2
|
作者
Yamashita, Hiroko [1 ,6 ]
Hatanaka, Kanako C. [2 ,3 ]
Yamagishi, Keisuke [4 ]
Saito, Yuria [4 ]
Hamasaki, Kengo [4 ]
Taniguchi, Mitsuru [4 ]
Okumura, Asami [3 ]
Nange, Ayae [3 ]
Matsuno, Yoshihiro [5 ]
Hatanaka, Yutaka [2 ,3 ]
机构
[1] Hokkaido Univ Hosp, Dept Breast Surg, Sapporo, Japan
[2] Hokkaido Univ Hosp, Ctr Dev Adv Diagnost, Sapporo, Japan
[3] Hokkaido Univ Hosp, Res Div Genome Compan Diagnost, Sapporo, Japan
[4] Sysmex Corp, Kobe, Japan
[5] Hokkaido Univ Hosp, Dept Surg Pathol, Sapporo, Japan
[6] Hokkaido Univ Hosp, Dept Breast Surg, Kita 8,Nishi 5,Kita Ku, Sapporo 0600808, Japan
关键词
95-Gene classifier; recurrence; ER -positive node; negative breast cancer; prediction model; PATIENT-LEVEL METAANALYSIS; GENE-EXPRESSION; CHEMOTHERAPY; RECURRENCE; TAMOXIFEN; EFFICACY; SUBTYPES; OUTCOMES; IMPACT; WOMEN;
D O I
10.21873/anticanres.16209
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: A subset of patients with estrogen receptor (ER)-positive, HER2-negative, and nodenegative breast cancer experience recurrences. Predicting patients who will have recurrences within 5 years of surgery is essential so that patients can be selected to receive adjuvant chemotherapy. The 95-gene classifier (95-GC) has been validated as a method to differentiate patients into high and low-risk groups for early recurrence. Patients andMethods: In this study, we performed 95-GC analysis on 56 formalin-fixed paraffin-embedded (FFPE) tissue samples from patients who underwent surgery for ER-positive, HER2negative, and node-negative breast cancer and did not receive adjuvant chemotherapy. We associated the obtained high- and low-risk groups with clinicopathological characteristics and recurrence-free survival (RFS). Results: We classified 12 out of 56 patients into the high-risk recurrence group. We found significantly higher KI67 scores in patients in the high-risk group. Other clinicopathological characteristics were not associated with the 95-GC risk groups. Patients in the 95-GC low-risk group had a significantly better prognosis than those in the high-risk group (p=0.0387). The 5-year RFS rate was 97.6% in the low-risk group and 74.1% in the high-risk group, while the 10-year RFS rates were 90.1% and 74.1%, respectively.Conclusion: The 95-GC score can accurately predict RFS within 5 years of surgery for ER-positive, HER2-negative, and node-negative breast cancer using FFPE tissue samples. These prediction models could help assign patients to the most effective treatment regimen.
引用
收藏
页码:707 / 711
页数:5
相关论文
共 50 条
  • [41] Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues
    Park, Sangjung
    Wang, Hye-Young
    Kim, Sunghyun
    Ahn, Sungwoo
    Lee, Dongsup
    Cho, Yoonjung
    Park, Kwang Hwa
    Jung, Dongju
    Kim, Seung Il
    Lee, Hyeyoung
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (10): : 6752 - 6759
  • [42] Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
    Buus, Richard
    Yeo, Belinda
    Brentnall, Adam R.
    Klintman, Marie
    Cheang, Maggie Chon U.
    Khabra, Komel
    Sestak, Ivana
    Gao, Qiong
    Cuzick, Jack
    Dowsett, Mitch
    BREAST CANCER RESEARCH, 2018, 20
  • [43] Mechanisms of primary AI resistance in ER-positive HER2-negative breast cancer.
    Miura, Daishu
    Iwatani, Tsuguo
    Kawabata, Hidetaka
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [45] Reply to: Prediction of benefit from chemotherapy in ER-positive/HER2-negative breast cancer
    Goldhirsch, A.
    Coates, A. S.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 755 - 755
  • [46] Gene expression analysis of formalin-fixed, paraffin-embedded breast cancer tissues using the multiplex branched DNA assay
    Landmark-Hoyvik, H.
    Dumeaux, V.
    Russnes, H. G.
    Jansen, L.
    Davies, J.
    Borresen-Dale, A. L.
    EJC SUPPLEMENTS, 2008, 6 (09): : 46 - 46
  • [47] Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients
    Musella, Valeria
    Callari, Maurizio
    Di Buduo, Eleonora
    Scuro, Manuela
    Dugo, Matteo
    Miodini, Patrizia
    Bianchini, Giampaolo
    Paolini, Biagio
    Gianni, Luca
    Daidone, Maria Grazia
    Cappelletti, Vera
    PLOS ONE, 2015, 10 (04):
  • [48] Technology Insight: application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer
    Paik, S
    Kim, CY
    Song, YK
    Kim, WS
    NATURE CLINICAL PRACTICE ONCOLOGY, 2005, 2 (05): : 246 - 254
  • [49] Proteomic Analysis of Stage-II Breast Cancer from Formalin-Fixed Paraffin-Embedded Tissues
    Al-Dhabi, Naif Abdullah
    Srigopalram, Srisesharam
    Ilavenil, Soundharrajan
    Kim, Young Ock
    Agastian, Paul
    Baaru, Rajasekhar
    Balamurugan, Kannan
    Choi, Ki Choon
    Arasu, Andmariadhas Valan
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [50] Investigation of Epstein-Barr virus DNA in formalin-fixed and paraffin-embedded breast cancer tissues
    Kalkan, A
    Ozdarendeli, A
    Bulut, Y
    Yekeler, H
    Cobanoglu, B
    Doymaz, MZ
    MEDICAL PRINCIPLES AND PRACTICE, 2005, 14 (04) : 268 - 271